NCT06278987 Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture
| NCT ID | NCT06278987 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Minnesota |
| Condition | Hip Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 150 participants in total. It began in 2024-10-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if patients with hip fractures who undergo cryoablation of the PENG have improved pain control 30 days from surgery when compared to those who have a fascia iliaca catheter.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing hip fracture repair aged 18-85. Exclusion Criteria: * Patients who have an exclusion to regional anesthesia. * Patients who are pregnant assessed via self-report or pregnancy test if they have taken one. * Non-English speakers * Patients who already had their fracture repaired"
Contact & Investigator
Candace Nelson
✉ nelso377@umn.eduJason Habeck
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT06278987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06278987 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06278987 currently recruiting?
Yes, NCT06278987 is actively recruiting participants. Contact the research team at nelso377@umn.edu for enrollment information.
Where is the NCT06278987 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06278987 clinical trial?
NCT06278987 is sponsored by University of Minnesota. The principal investigator is Jason Habeck at University of Minnesota. The trial plans to enroll 150 participants.